Response by Lei Et Al to Letter Regarding Article, "modernized Classification of Cardiac Antiarrhythmic Drugs".

Dan Hu,Yan Huang,Congxin Huang

DOI: https://doi.org/10.1161/circulationaha.118.039292

IF: 37.8

2019-01-01

Circulation

Abstract:HomeCirculationVol. 139, No. 13Letter by Hu et al Regarding Article, “Modernized Classification of Cardiac Antiarrhythmic Drugs” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLetter by Hu et al Regarding Article, “Modernized Classification of Cardiac Antiarrhythmic Drugs” Dan Hu, MD, PhD, Yan Huang, MD, PhD and Congxin Huang, MD, PhD Dan HuDan Hu Department of Cardiology and Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Hubei, China (D.H., Y.H., C.H.). Hubei Key Laboratory of Cardiology, Wuhan, China (D.H., Y.H., C.H.). Search for more papers by this author , Yan HuangYan Huang Department of Cardiology and Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Hubei, China (D.H., Y.H., C.H.). Hubei Key Laboratory of Cardiology, Wuhan, China (D.H., Y.H., C.H.). Search for more papers by this author and Congxin HuangCongxin Huang Department of Cardiology and Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Hubei, China (D.H., Y.H., C.H.). Hubei Key Laboratory of Cardiology, Wuhan, China (D.H., Y.H., C.H.). Search for more papers by this author Originally published25 Mar 2019https://doi.org/10.1161/CIRCULATIONAHA.118.038831Circulation. 2019;139:1650–1651To the Editor:The classification of antiarrhythmic drugs (AADs) was proposed by Vaughan Williams1 and supplemented by other researchers. This classification assigns drugs to 4 categories based on the electrophysiological characteristics of their actions. Since their introduction in 1970, AADs are still widely recognized and used in clinical practice. However, as time goes on, more novel AADs appear, and the mechanisms are being well explored, but they are still incomplete. Therefore, the classification of AADs needs to be more precise.To commemorate the centennial anniversary of Professor Vaughan Williams’s birth, Lei and colleagues2 redefined the AADs as 8 classes, including 32 types, which will greatly advance treatment decision in current clinical practice and help develop new AADs in the future. This new classification summarized the progress of AADs over the past half century, covered all the major mechanisms known currently, included specific electrophysiological targets associated with cardiac electrophysiology, and will provide valuable guidance for our understanding of arrhythmia and AADs.The importance and influence of this article are self-evident; however, we still have several questions to address. First, because so many conceptual drugs are newly enrolled, we are wondering why some promising targets are not included, such as those acting on the inward rectifying K+ channels, the small-conductance Ca2+-activated K+ channels, the 2-pore K+ channels, the stretch-activated nonselective cation channels, and galectin-3–related drugs, which have been profoundly investigated and recently considered to be influential to arrhythmia.3 It is well known that flecainide and propafenone are class Ic sodium channel blockers with a negative result from the CAST trial (Cardiac Arrhythmias Suppression Trial). We do recognize the significant progress on discovering other mechanisms of these 2 drugs, such as the cardiac ryanodine receptor type 2 blocking effect, and their application on catecholaminergic polymorphic ventricular tachycardia and Andersen-Tawil syndrome. But is it appropriate to enroll them in both class Ic and IVb, whereas many other drugs could also fall into multiple classes? Third, ATP-sensitive potassium channel openers (class IIIb), like nicorandil and pinacidil, are mainly used for dilating the smooth muscle cells to treat hypertension and angina. Because there is not enough evidence to support them as AADs directly, could the authors explain the reason to include ATP-sensitive potassium channel openers in the current class? How about their multiple-organ effect other than the heart, such as pancreas and brain? Furthermore, regarding either a compound (eg, Wenxin Keli and Shensong Yangxin) or a monomer (eg, acacetin), we sincerely wish that there might be some possibility for the traditional Chinese antiarrhythmic medicine to be included in the future.3–5 Last, there is a mistake that needs to be mentioned in Table II of the online-only Data Supplement: nicorandil, pinacidil, and diazoxide belong to ATP-sensitive potassium channel openers/agonists, not blockers.DisclosuresThe present study was supported by National Natural Science Foundation of China (No. 81670304); Distinguished Professor of Chutian scholar program of Hubei province. The authors report no conflicts.Footnoteshttps://www.ahajournals.org/journal/circReferences1. Vaughan Williams EM. Classification of antidysrhythmic drugs.Pharmacol Ther B. 1975; 1:115–138.MedlineGoogle Scholar2. Lei M, Wu L, Terrar DA, Huang CL. Modernized classification of cardiac antiarrhythmic drugs.Circulation. 2018; 138:1879–1896. doi: 10.1161/CIRCULATIONAHA.118.035455LinkGoogle Scholar3. Calvo D, Filgueiras-Rama D, Jalife J. Mechanisms and drug development in atrial fibrillation.Pharmacol Rev. 2018; 70:505–525. doi: 10.1124/pr.117.014183CrossrefMedlineGoogle Scholar4. Hu D, Barajas-Martínez H, Burashnikov A, Panama BK, Cordeiro JM, Antzelevitch C. Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: experimental and theoretical analysis.Int J Cardiol. 2016; 207:326–334. doi: 10.1016/j.ijcard.2016.01.016CrossrefMedlineGoogle Scholar5. Li GR, Wang HB, Qin GW, Jin MW, Tang Q, Sun HY, Du XL, Deng XL, Zhang XH, Chen JB, Chen L, Xu XH, Cheng LC, Chiu SW, Tse HF, Vanhoutte PM, Lau CP. Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs.Circulation. 2008; 117:2449–2457. doi: 10.1161/CIRCULATIONAHA.108.769554LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails March 26, 2019Vol 139, Issue 13 Advertisement Article InformationMetrics © 2019 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.118.038831PMID: 30908103 Originally publishedMarch 25, 2019 PDF download Advertisement SubjectsArrhythmias